First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

NCT05216432 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

930

Enrollment

INDUSTRY

Sponsor class

Conditions

PIK3CA Mutation
Solid Tumor, Adult
HER2-negative Breast Cancer
Breast Cancer
Metastatic Breast Cancer
Advanced Breast Cancer
Unresectable Solid Tumor

Interventions

DRUG: RLY-2608
DRUG: Fulvestrant
DRUG: Palbociclib 125mg
DRUG: Ribociclib 400mg
DRUG: Ribociclib 600mg
DRUG: PF-07220060 100mg
DRUG: PF-07220060 300 mg

Sponsor

Relay Therapeutics, Inc.